# Regeneron Pharmaceuticals share price today (Regeneron Pharmaceuticals, Inc., REGN)

> Regeneron Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. REGN · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/regn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $902.58 (+37.3% in a year)
- P/E: 20.0×, over 4.6 years
- Revenue (Jun 2026): $4.3 B (+16.7% on a year ago)
- Profit (Jun 2026): $1.3 B (−6.8% on a year ago)
- Operating margin: 33.1% (+3.5 points on a year ago)
- ROE: 14%, FY25
- ROIC: 16.3%, against a 4.7% cost of capital: +11.6 points

The main question: the share price moved +37.3% in a year while yearly earnings per share moved +8.2%. The difference came from the market paying a higher multiple. ## What is the Regeneron Pharmaceuticals share price today? Regeneron Pharmaceuticals, Inc.'s share price was $902.58 at the close on 5 November 2026. It has been rising for 5 weeks. That is 21.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $610 and $928, and at that close it sat 92% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row. Over the last 10 years the share price moved +139% while the S&P 500 moved +245%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Regeneron Pharmaceuticals pay? Regeneron Pharmaceuticals, Inc. paid $3.64 per share over the last four reported quarters. The most recent declaration was $0.94 for Jun 2026. At today's price of $902.58 that is a yield of 0.40%, based on dividends already paid, not a forecast. ## Which stock lists is Regeneron Pharmaceuticals on? Regeneron Pharmaceuticals is on 2 of our US lists: Nasdaq 100 companies and S&P 500 companies. - [Nasdaq 100 companies](https://www.sectoralpha.in/nasdaq-100-stocks)
- [S&P 500 companies](https://www.sectoralpha.in/sp-500-stocks)

## Is Regeneron Pharmaceuticals profitable? Regeneron Pharmaceuticals, Inc. earned $1.3 B of net profit in the Jun 2026 quarter, −6.8% on the same quarter a year earlier. Full-year FY25 profit was $4.5 B. Over 4 years profit has grown −13.6% a year on average. That is 30.2% of the quarter's revenue. The same quarter a year earlier earned $1.4 B. For the full year, FY25 profit was $4.5 B (+2.1% on the year before). Why profit moved: revenue changed +16.7% on a year earlier and the margin moved +3.5 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −4.0% and revenue +9.8%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Regeneron Pharmaceuticals make, and is it growing? Regeneron Pharmaceuticals, Inc. reported $4.3 B of revenue in the Jun 2026 quarter, +16.7% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 4 years it has grown −2.8% a year on average. The last full year, FY25, came in at $14.3 B. The last four reported quarters add to $15.5 B. FY25 revenue was $14.3 B, +1.0% on the year before. Recent pace: the last four quarters grew +9.8% on average, against −2.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +9.3%, against +7.3% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −2.9%, against +0.1% a year (stabilising). ## How much of every $100 of sales does Regeneron Pharmaceuticals keep? Regeneron Pharmaceuticals, Inc.'s operating margin was 33.1% in the Jun 2026 quarter, 3.5 percentage points higher than the same quarter a year ago. Across 5 years it has been between 25.8% and 56.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +3.5 percentage points on the year while gross margin changed +1.6 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Regeneron Pharmaceuticals' profit turning into cash? Over the last 3 years, 109% of Regeneron Pharmaceuticals, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $5.0 B of operating cash against $4.5 B of profit. After $898 M of spending on assets, $4.1 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Regeneron Pharmaceuticals' cash go? Regeneron Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.4 B on assets over the last 3 years. Averaged over those years that is 5.5% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.4 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Regeneron Pharmaceuticals' P/E ratio, and how does it compare with its own history? Regeneron Pharmaceuticals, Inc.'s P/E is 20.0×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +8.2% while the price moved +37.3%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +3.4% a year; about +4.9% a year came from earnings growth and about −1.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Regeneron Pharmaceuticals business getting better or worse? Regeneron Pharmaceuticals, Inc.'s business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 11.8%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Regeneron Pharmaceuticals earn on its capital? Regeneron Pharmaceuticals, Inc. earned a ROE of 14% in FY25. Its return on capital used (ROIC) is 11.6 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 31.4% net margin and 0.35× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 31.4% net margin × 0.35× asset turnover × 1.30× leverage (assets divided by equity) ≈ 14.3% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 16.3% − 4.7% = +11.6 percentage points. The 4.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 16.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 13.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Regeneron Pharmaceuticals have too much debt? Regeneron Pharmaceuticals, Inc. has total debt of $2.7 B against shareholder equity of $31.7 B as of Jun 2026, so its debt is 0.09× its equity, which is very little. Year by year, that ratio went from 0.14 in FY21 to 0.10 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Regeneron Pharmaceuticals shareholding pattern? 2.2% of Regeneron Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Regeneron Pharmaceuticals from balance-sheet trouble? For Regeneron Pharmaceuticals, Inc., the Z-score is 6.44. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 6.44 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Regeneron Pharmaceuticals rank in its industry? 52.8 out of 100, rank 13 of 30 in Biotechnology, with 81% of the evidence available. Regeneron Pharmaceuticals, Inc. scores 52.8 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 13. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 16.2 + 15.2 + 9.1 + 12.3 = 52.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Regeneron Pharmaceuticals compared with? Regeneron Pharmaceuticals ranks 13 of 30 Biotechnology companies on the 4-Factor Sector Score, with 52.8 out of 100. 1. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) EXEL · breaking out · Most evidence points up · 81% evidence 76.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/35 · Revenue 9.3% · Profit 42.8% · Operating margin change 1.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 46.5% · Operating margin 39.5% · 76% evidence Valuation 14.6/20 · P/E 15.9× · PEG 0.3 · 65% evidence Relative strength 17.9/20 · Lead over its industry 9.7% · Lead over S&P 500 35.4% · 1 year 68.4% · 100% evidence · 8 of 12 weeks ahead Exact sum: 22.7 + 20.9 + 14.6 + 17.9 = 76.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Halozyme Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/halo) HALO · leader · Most evidence points up · 81% evidence 72.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.7/35 · Revenue 41.1% · Profit -25.9% · Operating margin change -2.4 points · 83% evidence Capital efficiency 20.9/25 · ROCE 42.3% · Operating margin 59.8% · 76% evidence Valuation 14.6/20 · P/E 22.4× · PEG 0.25 · 65% evidence Relative strength 18.8/20 · Lead over its industry 21.7% · Lead over S&P 500 48.8% · 1 year 80.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.7 + 20.9 + 14.6 + 18.8 = 72 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) INCY · turning · Most evidence points up · 71% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 26.9% · Profit 85.3% · Operating margin change 16.3 points · 83% evidence Capital efficiency 20.5/25 · ROCE 28.1% · Operating margin 41.9% · 76% evidence Valuation 10.9/20 · P/E 14× · PEG n/a · 15% evidence Relative strength 7.2/20 · Lead over its industry -12.7% · Lead over S&P 500 8.2% · 1 year 11.4% · 100% evidence · 5 of 12 weeks ahead Exact sum: 27.1 + 20.5 + 10.9 + 7.2 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) GMAB · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.0/35 · Revenue 18.2% · Profit -39.3% · Operating margin change -3.7 points · 83% evidence Capital efficiency 15.6/25 · ROCE 11.7% · Operating margin 35.2% · 76% evidence Valuation 15.1/20 · P/E 21.4× · PEG 0.21 · 65% evidence Relative strength 19.5/20 · Lead over its industry 33.6% · Lead over S&P 500 65.2% · 1 year 83.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11 + 15.6 + 15.1 + 19.5 = 61.2 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak. 5. [argenx SE](https://www.sectoralpha.in/us/stocks/argx) ARGX · turning · Evidence leans up · 85% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.9/35 · Revenue 60.6% · Profit 22.4% · Operating margin change 5.9 points · 95% evidence Capital efficiency 17.1/25 · ROCE 18.9% · Operating margin 36.3% · 76% evidence Valuation 10.4/20 · P/E 32× · PEG 1.39 · 65% evidence Relative strength 8.4/20 · Lead over its industry -17.4% · Lead over S&P 500 2.7% · 1 year 4.7% · 100% evidence · 6 of 12 weeks ahead Exact sum: 24.9 + 17.1 + 10.4 + 8.4 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) ONC · leader · Evidence leans up · 64% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 34.3% · Profit n/a · Operating margin change 12.4 points · 62% evidence Capital efficiency 13.3/25 · ROCE 13.1% · Operating margin 19.1% · 76% evidence Valuation 9.1/20 · P/E 48.3× · PEG n/a · 15% evidence Relative strength 12.2/20 · Lead over its industry -6.3% · Lead over S&P 500 16.5% · 1 year 21.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23 + 13.3 + 9.1 + 12.2 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Kymera Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/kymr) KYMR · turning · Evidence leans up · 61% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit n/a · Operating margin change 620.5 points · 62% evidence Capital efficiency 6.8/25 · ROCE -22% · Operating margin -116.3% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 16.9/20 · Lead over its industry 11% · Lead over S&P 500 36.2% · 1 year 118.4% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.9 + 6.8 + 10 + 16.9 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) SYRE · quiet · Too little evidence to rank firmly · 56% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue n/a · Profit n/a · Operating margin change 999.3 points · 52% evidence Capital efficiency 8.6/25 · ROCE -24.5% · Operating margin n/a · 61% evidence Valuation 11.0/20 · P/E -8.2× · PEG n/a · 15% evidence Relative strength 12.9/20 · Lead over its industry 21.2% · Lead over S&P 500 46.6% · 1 year 328.9% · 100% evidence · 4 of 12 weeks ahead Exact sum: 23.6 + 8.6 + 11 + 12.9 = 56.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) MRNA · leader · Evidence leans up · 64% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.4/35 · Revenue -27.6% · Profit n/a · Operating margin change 80.8 points · 62% evidence Capital efficiency 6.5/25 · ROCE -28.9% · Operating margin -557.9% · 76% evidence Valuation 11.2/20 · P/E -11.6× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 161.6% · Lead over S&P 500 205.6% · 1 year 882.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.4 + 6.5 + 11.2 + 20 = 55.1 · What this means: Relative strength against the index is 205.6%, and revenue and profit growth are weak. 10. [Krystal Biotech, Inc.](https://www.sectoralpha.in/us/stocks/krys) KRYS · quiet · Evidence leans up · 81% evidence 55.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 22.6% · Profit 65.1% · Operating margin change 8 points · 83% evidence Capital efficiency 16.1/25 · ROCE 14.4% · Operating margin 49% · 76% evidence Valuation 12.4/20 · P/E 45.4× · PEG 0.77 · 65% evidence Relative strength 4.1/20 · Lead over its industry -19% · Lead over S&P 500 0.1% · 1 year 51.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 22.4 + 16.1 + 12.4 + 4.1 = 55 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) JAZZ · quiet · Evidence leans up · 74% evidence 55.0 out of 100 Growth Capital Valuation Relative
12. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) RPRX · turning · Evidence leans up · 81% evidence 53.7 out of 100 Growth Capital Valuation Relative
13. Regeneron Pharmaceuticals, Inc. this page REGN · leader · Evidence leans up · 81% evidence 52.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.2/35 · Revenue 9.3% · Profit -2.9% · Operating margin change 3.5 points · 83% evidence Capital efficiency 15.2/25 · ROCE 11.5% · Operating margin 33.1% · 76% evidence Valuation 9.1/20 · P/E 14.7× · PEG 2.06 · 65% evidence Relative strength 12.3/20 · Lead over its industry -4.8% · Lead over S&P 500 18.5% · 1 year 37.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 16.2 + 15.2 + 9.1 + 12.3 = 52.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 14. [Alnylam Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/alny) ALNY · basing · Evidence leans up · 64% evidence 51.6 out of 100 Growth Capital Valuation Relative
15. [Protagonist Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptgx) PTGX · losing its lead · Evidence leans down · 74% evidence 49.6 out of 100 Growth Capital Valuation Relative
16. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) VRTX · breaking out · Evidence leans down · 85% evidence 46.9 out of 100 Growth Capital Valuation Relative
17. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) TECH · turning · Evidence leans down · 74% evidence 44.4 out of 100 Growth Capital Valuation Relative
18. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) ROIV · turning · Too little evidence to rank firmly · 60% evidence 39.5 out of 100 Growth Capital Valuation Relative
19. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) SMMT · breaking out · Too little evidence to rank firmly · 53% evidence 39.2 out of 100 Growth Capital Valuation Relative
20. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) RVMD · quiet · Too little evidence to rank firmly · 53% evidence 38.7 out of 100 Growth Capital Valuation Relative
21. [Madrigal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mdgl) MDGL · quiet · Evidence leans down · 61% evidence 37.2 out of 100 Growth Capital Valuation Relative
22. [Insmed Incorporated](https://www.sectoralpha.in/us/stocks/insm) INSM · basing · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
23. [BridgeBio Pharma, Inc.](https://www.sectoralpha.in/us/stocks/bbio) BBIO · quiet · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
24. [BioNTech SE](https://www.sectoralpha.in/us/stocks/bntx) BNTX · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [BioMarin Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/bmrn) BMRN · quiet · Most evidence points down · 81% evidence 26.8 out of 100 Growth Capital Valuation Relative
26. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) ASND · turning · Too little evidence to rank firmly · 44% evidence 63.3 out of 100 Growth Capital Valuation Relative
27. Apogee Therapeutics, Inc. APGE · Too little evidence to rank firmly · 27% evidence 47.2 out of 100 Growth Capital Valuation Relative
28. Nuvalent, Inc. NUVL · Too little evidence to rank firmly · 20% evidence 41.2 out of 100 Growth Capital Valuation Relative
29. [Crinetics Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/crnx) CRNX · Too little evidence to rank firmly · 35% evidence 38.0 out of 100 Growth Capital Valuation Relative
30. Vaxcyte, Inc. PCVX · breaking out · Too little evidence to rank firmly · 47% evidence 37.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Biotechnology](https://www.sectoralpha.in/us/sectors/biotechnology), all 30 compared on one page. ## Which companies are close to Regeneron Pharmaceuticals in size? Regeneron Pharmaceuticals is the 3rd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Vertex Pharmaceuticals Incorporated and Moderna, Inc. Just below it: argenx SE, BeOne Medicines AG, Royalty Pharma plc and Revolution Medicines, Inc. ### Biotechnology companies close in size

1. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) $137.6 billion
2. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) $96.3 billion
3. Regeneron Pharmaceuticals, Inc. $90.6 billion
4. [argenx SE](https://www.sectoralpha.in/us/stocks/argx) $55 billion
5. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) $44.1 billion
6. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) $38.8 billion
7. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) $38.1 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Waste Management, Inc.](https://www.sectoralpha.in/us/stocks/wm) $94.7 billion · Waste Management
2. [Elevance Health, Inc.](https://www.sectoralpha.in/us/stocks/elv) $93.8 billion · Healthcare Plans
3. Regeneron Pharmaceuticals, Inc. $93.4 billion
4. [ING Groep N.V.](https://www.sectoralpha.in/us/stocks/ing) $92.8 billion · Banks - Diversified
5. [Agnico Eagle Mines Limited](https://www.sectoralpha.in/us/stocks/aem) $92.7 billion · Gold

## What else do people ask about Regeneron Pharmaceuticals? ### What were Regeneron Pharmaceuticals's latest quarterly results? Regeneron Pharmaceuticals, Inc. reported revenue of $4.3 B and net profit of $1.3 B for the Jun 2026 quarter. Revenue rose 16.7% and profit fell 6.8% compared with a year earlier. Earnings per share were $12.23. The operating margin was 33.1%, 3.5 percentage points higher than a year earlier (as of 5 November 2026). ### What is Regeneron Pharmaceuticals's market cap? Regeneron Pharmaceuticals, Inc.'s market capitalisation is $90.6 B at a stock price of $902.58. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Regeneron Pharmaceuticals performing? Regeneron Pharmaceuticals, Inc.'s share price has been rising for 5 weeks. In its latest quarter, revenue rose 16.7% and profit fell 6.8% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 15 weeks running (as of 5 November 2026). ### Will Regeneron Pharmaceuticals's stock price go up? This page does not forecast Regeneron Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $902.58, and it has been rising for 5 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Regeneron Pharmaceuticals have too much debt? No, Regeneron Pharmaceuticals, Inc. has little debt: its debt is 0.08× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 5 November 2026). ### Where is Regeneron Pharmaceuticals in its business cycle? Regeneron Pharmaceuticals, Inc.'s FY25 operating margin was 25.8%, against a 5-year range of 25.8% to 56.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 33.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Regeneron Pharmaceuticals story? The main question: the share price moved +37.3% in a year while yearly earnings per share moved +8.2%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Regeneron Pharmaceuticals a stock worth studying right now? What the numbers show: Regeneron Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). ## Lists

- Nasdaq 100 companies: https://www.sectoralpha.in/nasdaq-100-stocks
- S&P 500 companies: https://www.sectoralpha.in/sp-500-stocks

This is research, not advice. We’re not SEBI-registered.